A clinical trial associated with leptin research was updated to completed status on September 11, 2026. The study, titled "Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion," is registered as NCT06033092 and was conducted in Phase 2.
According to the registry entry, the trial status now reads COMPLETED as of the listed date. No results, outcomes, or efficacy data are included in this update. The record reflects only a change in trial status, not any findings or conclusions about tamoxifen, lifestyle interventions, or leptin.
Leptin remains an approved compound, and this trial update does not alter that regulatory status. Readers should note that a completed status indicates the study has finished its planned activities, but it does not by itself confirm what, if anything, was found. Further details, including any posted results, would need to be reviewed separately through the official registry listing.
For background on leptin, including its approved uses and general profile, readers can consult the compound overview page.